Risk factors associated with high-dose methotrexate induced toxicities

References

• Bedoui Y, Guillot X, Selambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019 Oct 10;20(20):5023. doi: 10.3390/ijms20205023
   PubMed Web of Science ®Google Scholar
• Chan ES, Cronstein BN Mechanisms of action of methotrexate. Bull Hosp Jt Dis (2013). 2013;71(Suppl 1):S5–8.
   PubMedGoogle Scholar
• Koźmiński P, Halik PK, Chesori R, et al. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int J Mol Sci. 2020 May 14;21(10):3483. doi: 10.3390/ijms21103483
   PubMed Web of Science ®Google Scholar
• Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020 Jun;47(6):4699–4708.
   PubMed Web of Science ®Google Scholar
• Alqarni AM, Zeidler MP. How does methotrexate work? Biochem Soc Trans. 2020 Apr 29;48(2):559–567. doi: 10.1042/BST20190803
   PubMed Web of Science ®Google Scholar
• Hanoodi M. Methotrexate. In: Mittal M, editor. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC; 2024. [updated 2023 Aug 16].
   Google Scholar
• Zhao Z, Hua Z, Luo X, et al. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother. 2022 Jun;150:113074. doi: 10.1016/j.biopha.2022.113074
   PubMed Web of Science ®Google Scholar
• Moshikur RM, Ali MK, Wakabayashi R, et al. Methotrexate-based ionic liquid as a potent anticancer drug for oral delivery: in vivo pharmacokinetics, biodistribution, and antitumor efficacy. Int J Pharm. 2021 Oct 25;608:121129. doi: 10.1016/j.ijpharm.2021.121129
   PubMedGoogle Scholar
• Fischer M, Siva S, Cook GK, et al. Methotrexate polyglutamate monitoring in patients with crohn’s disease. Clin Pharmacol Drug Dev. 2017 May;6(3):240–245.
   PubMed Web of Science ®Google Scholar
• Mei S, Li X, Jiang X, et al. Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. J Pharm Sci. 2018 May;107(5):1454–1460.
   PubMed Web of Science ®Google Scholar
• Puig L. Methotrexate: new therapeutic approaches. Actas Dermosifiliogr. 2014 Jul;105(6):583–589. doi: 10.1016/j.ad.2012.11.017
   PubMedGoogle Scholar
• Reed DR, Pierce EJ, Sen JM, et al. A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate. Cancer Manag Res. 2019;11:8065–8072. doi: 10.2147/CMAR.S190084
   PubMed Web of Science ®Google Scholar
• Wang CP Monitoring and treatment of acute kidney injury in children with acute lymphoblastic leukemia after high dose methotrexate chemotherapy. Iran J Pharm Res. 2016 Fall;15(4):957–961.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018 Oct 5;158:502–516. doi: 10.1016/j.ejmech.2018.09.027
   PubMed Web of Science ®Google Scholar
• Xu M, Wu S, Wang Y, et al. Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia. Front Pharmacol. 2022;13:1003812. doi: 10.3389/fphar.2022.1003812
   PubMed Web of Science ®Google Scholar
• Cheng Y, Chen MH, Zhuang Q, et al. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
   PubMed Web of Science ®Google Scholar
• Giletti A, Esperon P. Genetic markers in methotrexate treatments. Pharmacogenomics J. 2018 Dec;18(6):689–703. doi: 10.1038/s41397-018-0047-z
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncology. 2016 Dec;21(12):1471–1482. doi: 10.1634/theoncologist.2015-0164
   Google Scholar
• Pannu AK. Methotrexate overdose in clinical practice. Curr Drug Metab. 2019;20(9):714–719. doi: 10.2174/1389200220666190806140844
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009 Sep;146(5):489–503. doi: 10.1111/j.1365-2141.2009.07765.x
   PubMed Web of Science ®Google Scholar
• Yang YY, Gao L, Ding N, et al. How to rescue high-dose methotrexate induced nephrotoxicity and literature review about hemodiafiltration? Pak J Pharm Sci. 2020 May;33(3):1163–1167.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010 Nov;30(6):570–81. doi: 10.1016/j.semnephrol.2010.09.005
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncology. 2006 Jun;11(6):694–703. doi: 10.1634/theoncologist.11-6-694
   Google Scholar
• Elbarbary NS, Ismail EA, Farahat RK, et al. Omega-3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: a randomized placebo-controlled study. Nutrition. 2016 Jan;32(1):41–47. doi: 10.1016/j.nut.2015.06.010
   PubMed Web of Science ®Google Scholar
• Barak AJ, Tuma DJ, Beckenhauer HC Methotrexate hepatotoxicity. J Am Coll Nutr. 1984;3(1):93–96. 10.1080/07315724.1984.10720041
   PubMed Web of Science ®Google Scholar
• Di Martino V, Verhoeven DW, Verhoeven F, et al. Busting the myth of methotrexate chronic hepatotoxicity. Nat Rev Rheumatol. 2023 Feb;19(2):96–110.
   PubMed Web of Science ®Google Scholar
• Hadi NR, Al-Amran FG, Swadi A. Metformin ameliorates methotrexate-induced hepatotoxicity. J Pharmacol Pharmacother. 2012 Jul;3(3):248–253. doi: 10.4103/0976-500X.99426
   PubMedGoogle Scholar
• Bath RK, Brar NK, Forouhar FA, et al. A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014 Oct;15(10):517–524. doi: 10.1111/1751-2980.12184
   PubMed Web of Science ®Google Scholar
• Behairy A, Elkomy A, Elsayed F, et al. Antioxidant and anti-inflammatory potential of spirulina and thymoquinone mitigate the methotrexate-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol. 2024 Mar;397(3):1875–1888.
   PubMed Web of Science ®Google Scholar
• Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol. 2011 Jan;86(1):98–101.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Bansal R, Wayne AS. Managing therapy-associated neurotoxicity in children with ALL. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):376–383. doi: 10.1182/hematology.2021000269
   PubMedGoogle Scholar
• Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol. 2002 Jul;19(5):319–27.
   PubMed Web of Science ®Google Scholar
• Lopez-De Suso D, Garcia-Salido A, Andion-Catalan M, et al. Methotrexate-induced stroke-like neurotoxicity: case report, 8 years of experience, and literature review. Pediatr Blood Cancer. 2022 Sep;69(9):e29627.
   PubMed Web of Science ®Google Scholar
• Strizhevskaya AM, Senzhapova ER, Dzamraev AZ, et al. Potential marker of the pharmacodynamic effect of high doses of methotrexate–homocysteine. Patol Fiziol Eksp Ter. 2014 Apr;2(1):40–44. doi: 10.17650/2313-805X.2015.2.1.82-89
   Google Scholar
• Derouiche F, Bôle-Feysot C, Naïmi D, et al. Hyperhomocysteinemia-induced oxidative stress differentially alters proteasome composition and activities in heart and aorta. Biochem Biophys Res Commun. 2014 Sep 26;452(3):740–5. doi: 10.1016/j.bbrc.2014.08.141
   PubMed Web of Science ®Google Scholar
• Hasan T, Arora R, Bansal AK, et al. Disturbed homocysteine metabolism is associated with cancer. Exp Mol Med. 2019 Feb 21;51(2):1–13. doi: 10.1038/s12276-019-0216-4
   PubMedGoogle Scholar
• Kim KY, Shin KY, Chang KA. Potential biomarkers for post-stroke cognitive impairment: a systematic review and meta-analysis. Int J Mol Sci. 2022 Jan 6;23(2):602. doi: 10.3390/ijms23020602
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ibarra F, Eivaz-Mohammadi S, Surapaneni S, et al. Methotrexate induced pancytopenia. Case Rep Rheumatol. 2014; 2014:679580.
   PubMedGoogle Scholar
• Hamed KM, Dighriri IM, Baomar AF, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022 Sep;14(9):e29518.
   PubMed Web of Science ®Google Scholar
• Georgiou KR, Scherer MA, King TJ, et al. Deregulation of the CXCL12/CXCR4 axis in methotrexate chemotherapy-induced damage and recovery of the bone marrow microenvironment. Int J Exp Pathol. 2012 Apr;93(2):104–114.
   PubMed Web of Science ®Google Scholar
• Fan J, Su YW, Hassanshahi M, et al. β-catenin signaling is important for osteogenesis and hematopoiesis recovery following methotrexate chemotherapy in rats. J Cell Physiol. 2021 May;236(5):3740–3751.
   PubMed Web of Science ®Google Scholar
• Heil SG. Genetics of high-dose methotrexate-induced oral mucositis: current perspectives. Pharmacogenomics. 2019 Jun;20(9):621–623. doi: 10.2217/pgs-2019-0062
   PubMed Web of Science ®Google Scholar
• Oosterom N, Griffioen PH, den Hoed MAH, et al. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. PLoS One. 2018;13(7):e0199574. doi: 10.1371/journal.pone.0199574
   PubMed Web of Science ®Google Scholar
• Van der Beek JN, Oosterom N, Pieters R, et al. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: a systematic review. Critical Reviews In Oncology/Hematology. 2019 Oct;142:1–8. doi: 10.1016/j.critrevonc.2019.07.003
   PubMed Web of Science ®Google Scholar
• Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020 Feb;16(2):207–228. doi: 10.1080/1744666X.2019.1705785
   PubMed Web of Science ®Google Scholar
• Altz-Smith M, Kendall LG Jr., Stamm AM. Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med. 1987 Jul;83(1):179–81. doi: 10.1016/0002-9343(87)90517-1
   PubMed Web of Science ®Google Scholar
• McLean-Tooke A, Aldridge C, Waugh S, et al. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford). 2009 Aug;48(8):867–871.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema AD, Krähenbühl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010 Feb 16;102(4):673–677.
   PubMed Web of Science ®Google Scholar
• Kasenda B, Rehberg M, Thürmann P, et al. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. Ann Hematol. 2012 Aug;91(8):1257–64.
   PubMed Web of Science ®Google Scholar
• Joerger M, Ferreri AJ, Krähenbühl S, et al. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol. 2012 Feb;73(2):240–247.
   PubMed Web of Science ®Google Scholar
• Koch HJ. Population methods in drug development and related fields. Clin Pharmacokinet. 1996 Aug;31(2):164. doi: 10.2165/00003088-199631020-00007
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004 Jan 26;90(2):353–8. doi: 10.1038/sj.bjc.6601472
   PubMed Web of Science ®Google Scholar
• Bezabeh S, Mackey AC, Kluetz P, et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncology. 2012;17(4):550–554. doi: 10.1634/theoncologist.2011-0431
   Google Scholar
• Boerrigter E, Crul M. A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin. Ann Pharm Fr. 2017 Sep;75(5):344–348. doi: 10.1016/j.pharma.2017.06.002
   PubMedGoogle Scholar
• Narumi K, Sato Y, Kobayashi M, et al. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3. Biopharm Drug Dispos. 2017 Dec;38(9):501–508.
   PubMed Web of Science ®Google Scholar
• Ranchon F, Vantard N, Henin E, et al. Delayed methotrexate elimination: incidence, interaction with antacid drugs, and clinical consequences? Hematol Oncol. 2018 Apr;36(2):399–406.
   PubMed Web of Science ®Google Scholar
• Reeves DJ, Moore ES, Bascom D, et al. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014 Sep;78(3):565–71.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44–9.
   PubMed Web of Science ®Google Scholar
• McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol. 1998 Jun;45(6):539–544. doi: 10.1046/j.1365-2125.1998.00719.x
   PubMed Web of Science ®Google Scholar
• Wight J, Ku M, Garwood M, et al. Toxicity associated with high-dose intravenous methotrexate for hematological malignancies. Leuk Lymphoma. 2022 Oct;63(10):2375–2382.
   PubMed Web of Science ®Google Scholar
• Liang CA, Su YC, Lin SJ, et al. Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review. Eur J Clin Pharmacol. 2023 Jun;79(6):789–800.
   PubMed Web of Science ®Google Scholar
• Wiczer T, Dotson E, Tuten A, et al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2016 Jun;22(3):430–6.
   PubMed Web of Science ®Google Scholar
• Le T, Su S, Shahriyari L. Investigating optimal chemotherapy options for osteosarcoma patients through a mathematical model. Cells. 2021 Aug 6;10(8):2009. doi: 10.3390/cells10082009
   PubMed Web of Science ®Google Scholar
• Oude Munnink T, van der Meer A, de Haan J, et al. Reversible impaired methotrexate clearance after platinum-based chemotherapy for osteosarcoma. Ther Drug Monit. 2019 Dec;41(6):693–695.
   PubMed Web of Science ®Google Scholar
• Peters GJ, van der Wilt CL, van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther. 2000 Aug;87(2–3):227–53.
   PubMed Web of Science ®Google Scholar
• Levinsen M, Rosthoj S, Nygaard U, et al. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol. 2015 Jan;75(1):59–66.
   PubMed Web of Science ®Google Scholar
• Vang SI, Schmiegelow K, Frandsen T, et al. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 2015 May;75(5):1089–93. doi: 10.1007/s00280-015-2717-8
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Bretton-Meyer U. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Leukemia. 2001 Jan;15(1):74–9. doi: 10.1038/sj.leu.2401986
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Ifversen M. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1996 Sep;13(5):433–41. doi: 10.3109/08880019609030855
   PubMed Web of Science ®Google Scholar
• Huber MH, Lee JS, Newman RA, et al. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Ann Oncol. 1996 Jan;7(1):59–63.
   PubMed Web of Science ®Google Scholar
• Sun K, Tao H, Ding T, et al. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma. J Clin Pharm Ther. 2022 Dec;47(12):2196–2204. doi: 10.1111/jcpt.13791
   PubMed Web of Science ®Google Scholar
• Huang C, Xia F, Xue L, et al. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3. Cancer Chemother Pharmacol. 2020 Feb;85(2):433–441.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei L, Guan Y, et al. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients. Ren Fail. 2020 Nov;42(1):1111–1117.
   PubMed Web of Science ®Google Scholar
• El-Sheikh AA, van den Heuvel JJ, Koenderink JB, et al. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229–235. doi: 10.1124/jpet.106.110379
   PubMed Web of Science ®Google Scholar
• Iwaki M, Shimada H, Irino Y, et al. Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs. Biol Pharm Bull. 2017;40(6):926–931. doi: 10.1248/bpb.b16-00970
   PubMed Web of Science ®Google Scholar
• Kawase A, Yamamoto T, Egashira S, et al. Stereoselective inhibition of methotrexate excretion by glucuronides of nonsteroidal anti-inflammatory drugs via multidrug resistance proteins 2 and 4. J Pharmacol Exp Ther. 2016 Feb;356(2):366–74.
   PubMed Web of Science ®Google Scholar
• Bian J, Zhao J, Zhao Y, et al. Impact of individual factors on DNA methylation of drug metabolism genes: a systematic review. Environ And Mol Mutagen. 2023 Aug;64(7):401–415.
   PubMed Web of Science ®Google Scholar
• Zang YN, Wang SZ, Qin Y, et al. Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 2019 Aug;57(8):402–407.
   PubMed Web of Science ®Google Scholar
• Wang SF, Huang KW, Chou YC, et al. Effect of co-medications and potential risk factors of high-dose methotrexate-mediated acute hepatotoxicity in patients with osteosarcoma. Cancer Med. 2023 Jun;12(11):12354–12364.
   PubMed Web of Science ®Google Scholar
• Zakaria AY, Labib RM, Abdelshafi SA, et al. Single nucleotide polymorphisms of ATP-Binding cassette Gene(ABCC3 rs4793665) affect high dose methotrexate-induced nephrotoxicity in children with osteosarcoma. Int J Curr Res Rev. 2021;13(19):49–57. 10.31782/IJCRR.2021.131921
   Google Scholar
• Zhang W, Zhang Q, Zheng TT, et al. Delayed high-dose methotrexate excretion and influencing factors in osteosarcoma patients. Chin Med J (Engl). 2016 Nov 5;129(21):2530–2534. doi: 10.4103/0366-6999.192781
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun L, Chen X, et al. A systematic review of population pharmacokinetic models of methotrexate. Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):143–164.
   PubMed Web of Science ®Google Scholar
• Li X, Sui Z, Jing F, et al. Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia. Cancer Manag Res. 2019;11:6265–6274. doi: 10.2147/CMAR.S207959
   PubMed Web of Science ®Google Scholar
• Latcha S, Gupta M, Lin IH, et al. High dose methotrexate-induced acute kidney injury: incidence, risk factors, and recovery. Kidney Int Rep. 2023 Feb;8(2):360–364. doi: 10.1016/j.ekir.2022.10.029
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hellberg M, Svensson P, et al. Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3-5. Nephrol Dial Transplant. 2018 Feb 1;33(2):342–348. doi: 10.1093/ndt/gfw466
   PubMed Web of Science ®Google Scholar
• Zaman T, Filipowicz R, Beddhu S. Implications and importance of skeletal muscle mass in estimating glomerular filtration rate at dialysis initiation. J Ren Nutr. 2013 May;23(3):233–6. doi: 10.1053/j.jrn.2013.01.028
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014 Mar 20;32(9):949–59. doi: 10.1200/JCO.2013.53.0808
   PubMed Web of Science ®Google Scholar
• Misaka KO, Suga Y, Staub Y, et al. Risk factors for delayed elimination of methotrexate in children, adolescents and young adults with osteosarcoma. In Vivo. 2020 Nov;34(6):3459–3465.
   PubMed Web of Science ®Google Scholar
• Young EP, Cheng WS, Bernhardt MB, et al. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 Apr;67(4):e28123.
   PubMed Web of Science ®Google Scholar
• Abe K, Maeda-Minami A, Ishizu T, et al. Risk factors for hepatic toxicity of high-dose methotrexate in patients with osteosarcoma. Anticancer Res. 2022 Feb;42(2):1043–1050.
   PubMed Web of Science ®Google Scholar
• Reiss SN, Buie LW, Adel N, et al. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016 Dec;95(12):2009–2015.
   PubMed Web of Science ®Google Scholar
• Kataoka T, Sakurashita H, Kajikawa K, et al. Low serum albumin level is a risk factor for delayed methotrexate elimination in high-dose methotrexate treatment. Ann Pharmacother. 2021 Oct;55(10):1195–1202.
   PubMed Web of Science ®Google Scholar
• Khera S, Sharma G, Negi V, et al. Hypoalbuminemia and not undernutrition predicts high-dose methotrexate-induced nephrotoxicity in children with acute lymphoblastic leukemia in resource-constrained centers. Pediatr Blood Cancer. 2022 Sep;69(9):e29738.
   PubMed Web of Science ®Google Scholar
• Amitai I, Rozovski U, El-Saleh R, et al. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol. 2020 Oct;38(4):584–588.
   PubMed Web of Science ®Google Scholar
• Barakat S, Assem H, Salama M, et al. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia? J Egypt Natl Canc Inst. 2022 Apr 18;34(1):17. doi: 10.1186/s43046-022-00122-7
   PubMed Web of Science ®Google Scholar
• Schofield RC, Ramanathan LV, Murata K, et al. Development and validation of a turbulent flow chromatography and tandem mass spectrometry method for the quantitation of methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:169–75. doi: 10.1016/j.jchromb.2015.08.025
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Fujiwara SI, Murahashi R, et al. Risk factors for high-dose methotrexate-induced nephrotoxicity. Int J Hematol. 2021 Jul;114(1):79–84.
   PubMed Web of Science ®Google Scholar
• Song Z, Hu Y, Liu S, et al. The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis. Front Pharmacol. 2021;12:757464.
   PubMed Web of Science ®Google Scholar
• Vlaming ML, Pala Z, van Esch A, et al. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res. 2009 May 1;15(9):3084–3093. doi: 10.1158/1078-0432.CCR-08-2940
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Bruun GH, Yang W, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012 Jan;22(1):1–8.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013 Feb 7;121(6):898–904. doi: 10.1182/blood-2012-08-452839
   PubMed Web of Science ®Google Scholar
• Martinez D, Muhrez K, Woillard JB, et al. Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity. Clin Pharmacol Ther. 2018 Oct;104(4):687–698.
   PubMed Web of Science ®Google Scholar
• Csordas K, Lautner-Csorba O, Semsei AF, et al. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2014 Aug;166(3):410–20.
   PubMed Web of Science ®Google Scholar
• Han JM, Choi KH, Lee HH, et al. Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis. Anticancer Drugs. 2022 Jan 1;33(1):75–79. doi: 10.1097/CAD.0000000000001125
   PubMed Web of Science ®Google Scholar
• Zeng H, Chen ZS, Belinsky MG, et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225–32.
   PubMed Web of Science ®Google Scholar
• Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007 Mar;26(1):153–81. doi: 10.1007/s10555-007-9049-z
   PubMed Web of Science ®Google Scholar
• Fotoohi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma. 2008 Mar;49(3):410–26. doi: 10.1080/10428190701824569
   PubMed Web of Science ®Google Scholar
• Simon N, Marsot A, Villard E, et al. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J. 2013 Dec;13(6):507–13.
   PubMed Web of Science ®Google Scholar
• Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 1993 May 1;81(9):2394–2398. doi: 10.1182/blood.V81.9.2394.2394
   PubMed Web of Science ®Google Scholar
• Kim IW, Yun HY, Choi B, et al. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis. Clin Ther. 2012 Aug;34(8):1816–26.
   PubMed Web of Science ®Google Scholar
• Gorczyca L, Aleksunes LM. Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species. Expert Opin Drug Metab Toxicol. 2020 Mar;16(3):239–253. doi: 10.1080/17425255.2020.1732348
   PubMed Web of Science ®Google Scholar
• Lui G, Treluyer JM, Fresneau B, et al. A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high-dose methotrexate: data from the OS2006/Sarcoma-09 trial. J Clin Pharmacol. 2018 Dec;58(12):1541–1549.
   PubMed Web of Science ®Google Scholar
• Koomdee N, Hongeng S, Apibal S, et al. Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2012;13(7):3461–4. doi: 10.7314/APJCP.2012.13.7.3461
   PubMedGoogle Scholar
• Wang SM, Sun LL, Zeng WX, et al. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2014 Aug;74(2):283–9.
   PubMed Web of Science ®Google Scholar
• Campbell JM, Bateman E, Stephenson MD, et al. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol. 2016 Jul;78(1):27–39.
   PubMed Web of Science ®Google Scholar
• Chae H, Kim M, Choi SH, et al. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia. J Chemother. 2020 Sep;32(5):251–259.
   PubMed Web of Science ®Google Scholar
• Chang X, Guo Y, Su L, et al. Influence of MTHFR C677T polymorphism on high-dose methotrexate-related toxicity in patients with primary central nervous system diffuse large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):91–96.
   PubMed Web of Science ®Google Scholar
• Maagdenberg H, Oosterom N, Zanen J, et al. Genetic variants associated with methotrexate-induced mucositis in cancer treatment: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021 May;161:103312. doi: 10.1016/j.critrevonc.2021.103312
   PubMed Web of Science ®Google Scholar
• Xu L, Wang L, Xue B, et al. MTHFR variant is associated with high-dose methotrexate-induced toxicity in the Chinese osteosarcoma patients. J Bone Oncol. 2018 Nov;13:143–147. doi: 10.1016/j.jbo.2018.10.002
   PubMed Web of Science ®Google Scholar
• Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol. 2012 Oct;33(5):1445–54. doi: 10.1007/s13277-012-0395-2
   PubMedGoogle Scholar
• Zhang W, Liu Z, Yang Z, et al. MTHFR polymorphism is associated with severe methotrexate-induced toxicity in osteosarcoma treatment. Front Oncol. 2021;11:781386. doi: 10.3389/fonc.2021.781386
   PubMed Web of Science ®Google Scholar
• Zhao M, Liang L, Ji L, et al. MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis. Pharmacogenomics. 2016 Jun;17(9):1005–17.
   PubMed Web of Science ®Google Scholar
• Hagleitner MM, Coenen MJ, Aplenc R, et al. The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. Pharmacogenomics J. 2014 Apr;14(2):115–119.
   PubMed Web of Science ®Google Scholar
• Te Loo DM, Hagleitner MM, Coenen MJ Is there a role for the MTHFR 677C>T and 1298A>C polymorphisms in methotrexate-induced liver toxicity? Pharmacogenomics. 2014 Aug;15(11):1401–1403.
   PubMed Web of Science ®Google Scholar
• Umerez M, Gutierrez-Camino A, Munoz-Maldonado C, et al. MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy. Pharmgenomics Pers Med. 2017;10:69–78. doi: 10.2147/PGPM.S107047
   PubMed Web of Science ®Google Scholar
• Yao P, He X, Zhang R, et al. The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis. Hematology. 2019 Dec;24(1):10–19.
   PubMed Web of Science ®Google Scholar
• Nakano T, Kobayashi R, Matsushima S, et al. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma. Int J Hematol. 2021 May;113(5):744–750.
   PubMed Web of Science ®Google Scholar
• Yang W, Karol SE, Hoshitsuki K, et al. Association of Inherited Genetic Factors with drug-induced hepatic damage among children with acute lymphoblastic leukemia. JAMA Netw Open. 2022 Dec 1;5(12):e2248803. doi: 10.1001/jamanetworkopen.2022.48803
   PubMed Web of Science ®Google Scholar
• Kim HS, Xiao X, Byun J, et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw Open. 2022 Oct 3;5(10):e2234221. doi: 10.1001/jamanetworkopen.2022.34221
   PubMed Web of Science ®Google Scholar
• Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007 Aug;127(8):1860–7.
   PubMed Web of Science ®Google Scholar
• Yousef AM, Farhad R, Alshamaseen D, et al. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019 Apr;83(4):755–762.
   PubMed Web of Science ®Google Scholar
• Oosterom N, Berrevoets M, den Hoed MAH, et al. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Pharmacogenet Genom. 2018 Oct;28(10):223–229.
   PubMed Web of Science ®Google Scholar
• Karpa V, Kalinderi K, Fidani L, et al. Association of microRNA polymorphisms with toxicities induced by methotrexate in children with acute lymphoblastic leukemia. Hematol Rep. 2023 Nov 20;15(4):634–650. doi: 10.3390/hematolrep15040065
   PubMed Web of Science ®Google Scholar
• Wang SM, Zeng WX, Wu WS, et al. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia. Leuk Res. 2018 Feb;65:61–66. doi: 10.1016/j.leukres.2018.01.004
   PubMed Web of Science ®Google Scholar
• Wang SM, Sun LL, Zeng WX, et al. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Med Oncol. 2014 Jul;31(7):62.
   PubMed Web of Science ®Google Scholar
• Wang SM, Zeng WX, Wu WS, et al. Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia. J Gene Med. 2017 Nov;19(11):353–359.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Umerez M, Santos B, et al. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicity. Epigenomics. 2018 Apr 1;10(4):409–417. doi: 10.2217/epi-2017-0138
   PubMed Web of Science ®Google Scholar
• Zhan M, Liu T, Zhang Z, et al. Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia. Front Pediatr. 2023;11:1153767. doi: 10.3389/fped.2023.1153767
   PubMed Web of Science ®Google Scholar
• Forster VJ, McDonnell A, Theobald R, et al. Effect of methotrexate/vitamin B(12) on DNA methylation as a potential factor in leukemia treatment-related neurotoxicity. Epigenomics. 2017 Sep;9(9):1205–1218. doi: 10.2217/epi-2016-0165
   PubMed Web of Science ®Google Scholar
• Wang SM, Kong XY, Li M, et al. Association of GGH Promoter Methylation Levels with methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Pharmacotherapy. 2020 Jul;40(7):614–622.
   PubMed Web of Science ®Google Scholar
• Chen YC, Sheen JM, Wang SC, et al. Methotrexate neurotoxicity is related to epigenetic modification of the myelination process. Int J Mol Sci. 2021 Jun 23;22(13):6718. doi: 10.3390/ijms22136718
   PubMed Web of Science ®Google Scholar
• Zager RA, Johnson AC, Becker K Renal Cortical Lactate Dehydrogenase: A Useful, Accurate, Quantitative Marker of In Vivo Tubular Injury and Acute Renal Failure. PloS One. 2013;8(6):e66776. 10.1371/journal.pone.0066776
   PubMed Web of Science ®Google Scholar